Clinical Trials

Phase 1b/2 clinical trial of single agent MRTX849 and in combinations in patients with advanced solid tumors that have a KRAS^G12C mutation. Combination cohorts include adagrasib with cetuximab, afatinib or pembrolizumab

Phase 1b/2 clinical trial of MRTX849 in combination with TNO155—a selective, orally bioavailable allosteric inhibitor of wild-type SHP2—in patients with a KRAS^G12C mutation

Phase 2 clinical trial of MRTX849 in combination with pembrolizumab in patients with advanced NSCLC with a KRAS^G12C mutation stratified by TPS score

Randomized Phase 3 clinical trial comparing MRTX849 in combination with cetuximab versus chemotherapy in patients with advanced colorectal cancer with KRAS^G12C mutation in the second-line setting

Randomized Phase 3 clinical trial of MRTX849 versus docetaxel in patients with previously treated non-small cell lung cancer with KRAS^G12C mutation

Phase 1/1b clinical trial of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRAS^G12C mutation

Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Phase 1/2 clinical trial of the SOS1 inhibitor, MRTX0902 as a monotherapy and in combination with MRTX849 (adagrasib) in patients with advanced solid tumors harboring mutations in the KRAS-MAPK pathway.